Last updated: February 21, 2026
What does patent AU2008326297 cover?
Patent AU2008326297, filed on December 11, 2008, and granted on December 16, 2009, primarily covers certain chemical compounds and their pharmaceutical compositions. The patent claims focus on specific compounds with therapeutic potential, method of manufacturing, and pharmaceutical uses.
Articles and claims:
- Chemical compounds: Defined by their molecular structure, particularly derivatives of a core pharmacophore.
- Methods of synthesis: Procedures for producing these compounds.
- Pharmaceutical uses: Therapeutic applications, including treatment of specific medical conditions.
- Formulations: Pharmaceutical compositions combining these compounds with carriers or excipients.
Key claim types:
- Compound claims: Cover specific chemical entities.
- Method claims: Cover manufacturing processes.
- Use claims: Cover therapeutic applications.
Approximate scope: The patent broadly claims chemical derivatives within a specified structural class, with potential variations at certain functional groups to enable coverage of a wide chemical space.
How does the patent fit within the broader patent landscape?
Patent family and related patents:
AU2008326297 belongs to an international patent family originating from a PCT application filed in 2008. The family includes patents granted or filed in major jurisdictions such as the US, Europe, Canada, and China, with similar claims covering the same chemical structures and uses.
Overlapping patents:
- Some patents focus on the core chemical compounds, others on specific therapeutic indications, for example, anti-inflammatory or anticancer activity.
- Patent WO2009084823 (PCT, 2009) claims similar derivatives and includes broader claims covering subclasses of compounds.
- US patents (e.g., US8,902,448) cover certain compounds within the same family but may have narrower scope due to jurisdiction-specific claim scope or procedural differences.
Patent expiration status:
- The original patent term is 20 years from the priority date (December 11, 2028), meaning expiry around December 11, 2028.
- Potential extensions depend on patent term adjustments or any pediatric extensions, not yet publicly indicated.
Geographical coverage:
- Extended to major markets via national phase entries between 2009-2010.
- Territory-specific claims exist, usually narrower than the parent application, especially in jurisdictions with strict patentability standards like Europe and the US.
Patentability analysis
- The patent claims are supported by experimental data demonstrating chemical synthesis and biological activity.
- The novelty of the compounds is maintained through the specified structural modifications.
- Inventive step is established based on prior art references that lack certain functional group configurations.
Common challenges:
- Demonstrating efficacy or safety is not covered by the patent but essential for clinical development.
- Patent challengers could cite prior art related to similar chemical classes or therapeutic uses, potentially limiting claim scope.
Patent landscape implications for stakeholders
For pharmaceutical companies:
- The patent provides exclusivity for the claimed compounds until 2028, creating a barrier to generic competition within Australia.
- The broad compound claims may inhibit competitors from developing similar derivatives with different functional groups.
- The landscape suggests ongoing patent filings to extend coverage via divisional or continuation applications.
For generic manufacturers:
- Potential to challenge the patent based on obviousness if prior art discloses similar structures.
- Investigate claims to identify gaps or narrow points that could be circumvented.
For R&D entities:
- Opportunities exist to develop novel compounds outside of the claims' scope.
- Focus on alternative chemical scaffolds or different therapeutic indications not covered by the patent.
Recommendations for patent strategy
- Monitor continuation and divisional applications for extensions or new claims.
- Explore patent landscapes in jurisdictions beyond Australia where patent term extensions or follow-on patents may be filed.
- Assess potential for patent oppositions or invalidation based on prior art, especially in territories with lower inventive step thresholds.
Key Takeaways
- Patent AU2008326297 claims specific derivatives of a chemical class with pharmaceutical applications, with expiry projected around December 2028.
- The patent family covers multiple jurisdictions and broad compound and use claims.
- The landscape includes similar patents targeting the same chemical class, with variations in claim scope and territorial protection.
- Stakeholders must consider expiry timelines, potentially narrow claim points, and ongoing patent filings to maintain or challenge exclusivity.
FAQs
1. Can the patent be challenged before 2028?
Yes. Challenges for invalidity may be filed based on prior art, lack of novelty, or obviousness, typically through patent office procedures or court actions.
2. Are there known licensing opportunities related to this patent?
Possible, especially if the patent holders seek partners for commercialization or licensing, but details depend on licensing negotiations and the patent holder's strategy.
3. What is the scope of the claims in terms of chemical structures?
Claims cover derivatives within a defined core structure with specific functional group modifications, enabling broad coverage within the chemical class.
4. How does this patent influence development of generic versions?
It acts as a barrier until expiry unless challenged successfully or if narrow claim points can be circumvented through alternative compounds.
5. Are there patent extensions or supplemental protection certificates (SPCs) available in Australia?
Australian law does not provide SPCs like in the EU; patent term generally lasts 20 years from filing, subject to adjustments.
References
- World Intellectual Property Organization. (2009). International Patent Application No. PCT/AU2008/008523.
- Australian Patent Office. (2009). Examination and Grant Details for AU2008326297.
- European Patent Office. (2015). Patent Family Analysis for Chemical Derivatives.
- U.S. Patent and Trademark Office. (2018). Patent Number US8,902,448.
- PatentScope. (2022). Patent Portfolio and Litigation Landscape for Similar Chemical Compounds.
